US 12,305,236 B2
Methods and systems for selection and treatment of patients with inflammatory diseases
Janine Bilsborough, Simi Valley, CA (US); Dermot P. McGovern, Los Angeles, CA (US); Stephan Targan, Los Angeles, CA (US); Alka Potdar, Cumming, CA (US); Jeffry D. Watkins, Encinitas, CA (US); and Cindy T. Dickerson, Encinitas, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US); and Prometheus Biosciences, Inc., San Diego, CA (US)
Appl. No. 17/051,731
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US); and PROMETHEUS BIOSCIENCES, INC., San Diego, CA (US)
PCT Filed Apr. 26, 2019, PCT No. PCT/US2019/029402
§ 371(c)(1), (2) Date Oct. 29, 2020,
PCT Pub. No. WO2019/212899, PCT Pub. Date Nov. 7, 2019.
Claims priority of provisional application 62/784,179, filed on Dec. 21, 2018.
Claims priority of provisional application 62/681,557, filed on Jun. 6, 2018.
Claims priority of provisional application 62/664,720, filed on Apr. 30, 2018.
Prior Publication US 2021/0238684 A1, Aug. 5, 2021
Int. Cl. C12Q 1/6883 (2018.01); A61P 1/00 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C12Q 1/6883 (2013.01) [A61P 1/00 (2018.01); A61P 37/06 (2018.01); C07K 16/2875 (2013.01); A61K 2039/505 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] 8 Claims
 
1. A method of inhibiting or reducing CD30 ligand (CD30L) activity or expression in a subject having inflammatory bowel disease (IBD), the method comprising:
a) identifying the subject as being a carrier of a genotype comprising a polymorphism at rs911605 and/or rs1006026, wherein the polymorphism at rs911605 has an “A” allele at nucleobase 501 within rs911605 (SEQ ID NO: 1), and wherein the polymorphism at rs1006026 has a “G” allele at nucleobase 501 within rs1006026 (SEQ ID NO: 3); and
b) administering to the subject an effective amount of an inhibitor of CD30 ligand to inhibit or reduce the CD30 ligand activity or expression in the subject.